Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin

Neurology

Volumn 51, Issue 6 SUPPL. 5, 1998, Pages

  Hahn, Angelika F ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; PREDNISONE;

ACTION POTENTIAL; ARTICLE; ATAXIA; AUTOIMMUNE DISEASE; BINDING AFFINITY; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; DEMYELINATION; DISABILITY; DRUG SAFETY; ELECTRODIAGNOSIS; GUILLAIN BARRE SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NERVE FIBER DEGENERATION; POLYNEUROPATHY; PRIORITY JOURNAL; RELAPSE;

EID: 0032423145     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.51.6_suppl_5.s16     Document Type: Article

References (75)

1. Dyck PJ, Giannini C, Lais A. Pathological alterations of nerves. In: Dyck PJ, Thomas PK, eds. Peripheral neuropathy. 3rd ed. Philadelphia: WB Saunders, 1993:514-595.
2. Hartung H-P, Reiners K, Toyka KV, Pollard JD. Guillain-Barré syndrome and CIDP. In: Hohlfeld R, ed. Immunology of neuromuscular disease. Dordrecht: Kluwer 1994:39-104.
3. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-637.
4. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
5. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electro-physiological study of 92 cases. Brain 1987;110:1617-1630.
6. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
7. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
8. Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: a review. Muscle Nerve 1994;17:1145-1155.
9. Moulin DE, Hagen N, Feasby TE, Amireh R, Hahn AF. Pain in Guillain-Barré syndrome. Neurology 1997;48:328-331.
10. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-2209.
11. Simmons Z, Albers JW, Bromberg MB, Feldman EL. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-568.
12. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children: I. Presentation, electrodiagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997;20:1008-1015.
13. Oh SJ, Joy JL, Kuruoglu R. "Chronic sensory demyelinating neuropathy": chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy. J Neurol Neurosurg Psychiatry 1992;55:677-680.
14. van Dijk GW, Notermans NC, Franssen H, Oey PL, Wokke JHJ. Response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy with only sensory symptoms. J Neurol 1996;243:318-322.
15. Donaghy M, Mills KR, Boniface SJ, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-783.
16. Thomas PK, Claus D, Jaspert A, et al. Focal upper limb demyelinating neuropathy. Brain 1996;119:765-774.
17. Thomas PK, Walker RWH, Ridge P, et al. Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. Brain 1987;110:53-76.
18. Rubin M, Karpati G, Carpenter S. Combined central and peripheral myelinopathy. Neurology 1987;37:1287-1290.
19. Mendell JR, Kolkin S, Kissel JT, Weiss KL, Chakeres DW, Rammohan K. Evidence for central nervous system demyelination in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987;37:1287-1290.
20. Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol 1991;30:54-61.
21. Notermans NC, Wokke JHJ, Lokhorst HM, Franssen H, van der Graaf Y, Jennekens GFI. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: a prospective study of the prognostic value of clinical and laboratory abnormalities. Brain 1994;117:1385-1393.
22. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
23. Albers JW, Kelly JJ. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435-451.
24. Valldeoriola F, Graus F, Steck AJ, et al. Delayed appearance of anti-myelin-associated glycoprotein antibodies in a patient with chronic demyelinating polyneuropathy. Ann Neurol 1993;34:394-396.
25. Bleasel AF, Hawke SHB, Pollard JD, McLeod JG. IgG monoclonal paraproteinemia and peripheral neuropathy. J Neurol Neurosurg Psychiatry 1993;56:52-57.
26. Suarez GA, Kelly JJ Jr. Polyneuropathy associated with monoclonal gammopathy of undetermined significance: further evidence that IgM-MGUS neuropathies are different than IgG-MGUS. Neurology 1993;43:1304-1308.
27. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795.
28. Yeung KB, Thomas PK, King RHM, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinemia. J Neurol 1991;238: 383-391.
29. Pollard JD, McCombe PA, Baverstock J, et al. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1986;13: 123-134.
30. Matsumuro K, Izumo S, Umehara F, Osame M. Chronic inflammatory demyelinating polyneuropathy: histopathological and immunopathological studies on biopsied sural nerves. J Neurol Sci 1994;127:170-178.
31. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 1996;19:474-487.
32. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981; 9(Suppl):134-145.
33. Hays AP, Lee SS, Latov N. Immune reactive C3d on the surface of myelin sheaths in neuropathy. J Neuroimmunol 1988;18:231-244.
34. Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39:625-635.
35. Griffin JW, George R, Lobato C, Tyor WR, Yan LC, Glass JD. Macrophage responses and myelin clearance during Wallerian degeneration: relevance to immune-mediated demyelination. J Neuroimmunol 1992;40:153-165.
36. Harvey GK, Pollard JD, Schiindheim K, Antony J. Chronic experimental allergic neuritis. An electrophysiological and histological study in the rabbit. J Neurol Sci 1987;81:215-225.
37. Hartung H-P, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part 1. Muscle Nerve 1995;18:137-153.
38. Hartung H-P, Willison H, Jung S, Pette M, Toyka KV, Giegerich G. Autoimmune responses in peripheral nerve. Springer Semin Immunopathol 1996;18:97-123.
39. Koski CL, Humphrey R, Shin ML. Anti-peripheral myelin antibody in patients with demyelinating neuropathy: quantitative and kinetic determination of serum antibody by complement component 1 fixation. Proc Natl Acad Sci USA 1985;82:905-909.
40. Fredman P, Vedeler CA, Nyland H, Aarli JA, Svennerholm L. Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM1 and sulphatide of peripheral nerve myelin. J Neurol 1991;238: 75-79.
41. Ilyas AA, Mithen FA, Dalakas MC, et al. Antibodies to sulfated glycolipids in Guillain-Barré syndrome. J Neurol Sci 1991;105:108-117.
42. Khalili-Shirazi A, Hughes RAC, Brostoff SW, Linnington C, Gregson N. T cell responses to myelin proteins in Guillain-Barré syndrome. J Neurol Sci 1992;111:200-203.
43. Khalili-Shirazi A, Atkinson P, Gregson N, Hughes RAC. Antibody responses to PO and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. J Neuroimmunol 1993;46:245-252.
44. Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P. Serum and CSF anti-GM1 antibodies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1993;114:49-55.
45. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996; 119:1055-1066.
46. Hahn AF, Feasby TE, Gilbert JJ. Blood-nerve barrier studies in experimental allergic neuritis. Acta Neuropathol (Berl) 1985;68:101-109.
47. Hahn AF, Feasby TE, Wilkie L, Lovgren D. Antigalactocerebroside antibody increases demyelination in adoptive transfer experimental allergic neuritis. Muscle Nerve 1993;16:1174-1180.
48. Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of non-neural specificity open the blood-nerve barrier to circulating antibody. Ann Neurol 1995;37:467-475.
49. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
50. Sladky JT, Brown MJ, Berman PH. Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder. Ann Neurol 1986;20:76-81.
51. Simmons Z, Wald JJ, Albers JW. Chronic inflammatory demyelinating polyradiculoneuropathy in children. II. Long-term follow-up, with comparison to adults. Muscle Nerve 1997;20: 1569-1575.
52. Dyck PJ, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
53. Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486.
54. Vermeulen M, van der Meché FGA, Speelman JD, Weber A, Busch HFM. Plasma and gamma-globulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-326.
55. Curro Dossi B, Tezzon F. High-dose intravenous gammaglobulin for chronic inflammatory demyelinating polyneuropathy. Ital J Neurol Sci 1987;8:321-326.
56. Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD. High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 1989;39:422-425.
57. van Doom PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990;29: 57-64.
58. Churchyard A, Day T, Grainger K, Mastaglia FL. Intravenous immunoglobulin therapy in the inflammatory neuropathies. Clin Exp Neurol 1991;28:168-179.
59. Cornblath DR, Chaudry V, Griffin JW. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991;30:104-106.
60. van Doom PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 1991;48:217-220.
61. van Doom PA, Brand A, Strengers PFW, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study (see comments). Neurology 1990;40:209-212.
62. Vermeulen M, van Doom PA, Brand A, Strengers PFW, Jennekens FGI, Busch HGM. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
63. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
64. Thompson N, Choudhary P, Hughes RAC, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243:280-285.
65. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-345.
66. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. Q J Med 1995;88:493-502.
67. Nevo Y, Pestronk A, Kornberg AJ, et al. Childhood chronic inflammatory demyelinating neuropathies: clinical course and long-term follow-up. Neurology 1996;47:98-102.
68. van Doom PA, Rossi F, Brand A, van Lint M, Vermeulen M, Kazatchkine MD. On the mechanism of high-dose intravenous immunoglobulin treatment of patients with chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1990;29: 57-64.
69. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol 1992;62: S82-86.
70. Kazatchkine MD. Mechanisms of action of intravenous immunoglobulin in immune-mediated diseases. In: Kazatchkine MD, Morell A, eds. Intravenous immunoglobulin research and therapy. London: Parthenon Publishing, 1996:29-41.
71. Miyagi F, Horiuchi H, Nagata I, et al. Fc portion of intravenous immunoglobulin suppresses the induction of experimental allergic neuritis. J Neuroimmunol 1997;78:127-131.
72. Saoudi A, Hurez V, de Kozak Y, et al. Human immunoglobulin preparations for intravenous use (IVIg) prevent experimental autoimmune uveoretinitis. Int Immunol 1993;5:1559-1567.
73. Anderson CL. Human IgG Fc receptors. Clin Immunol Immunopathol 1989;53:S63-71.
74. Stangel M, Hartung H-P, Marx P, Gold R. Intravenous immunoglobulin treatment of neurological autoimmune diseases. J Neurol Sci 1998;153:203-214.
75. Prick MJJ, Verhagen WIM. Chronic inflammatory demyelinating polyneuropathy: immunoglobulins or plasmapheresis? Arch Neurol 1991;48:1118-1119.